QIFENG
873169
LEETRO
430425
KSEC Intelligent Technology
301311
4
Guangdong Topstar Technology
300607
5
Hengerda New Materials
300946
CN Stock MarketDetailed Quotes
688212 Shanghai Aohua Photoelectricity Endoscope
- 47.14
- +0.77+1.66%
Market Closed May 12 15:00 CST
6.35BMarket Cap-604.36P/E (TTM)
47.38High46.00Low11.32KlotVolume46.50Open46.37Pre Close52.91MTurnover0.84%Turnover Ratio302.18P/E (Static)134.67MShares58.0052wk High4.83P/B6.35BFloat Cap31.5152wk Low55.64Limit Up134.67MShs Float83.70Historical High37.10Limit Down2.98%Amplitude31.51Historical Low0.30Dividend TTM46.73Avg Price5.65KlotAsk0.64%Div YieldTTM100Lot Size5.10KlotBid
Shanghai Aohua Photoelectricity Endoscope News
Direct coverage of the Star medical instruments industry collective Earnings Conference: Multiple companies are laying out AI medical Business, and key segments in innovation fields may accelerate the development of domestic production.
① Attending companies believe that tariff policies will bring some cost pressures and market challenges to enterprises, but at the same time, it has accelerated the localization process in relevant fields; ② Some attending companies disclosed the latest developments in their Business during the earnings briefing and the planning for related lines by 2025.
Australian and Chinese Endoscopy: Report for the first quarter of 2025
2025 First Quarter Report
Aohua Endoscopy (688212.SH): has repurchased a cumulative 1.02% of the company's shares.
On April 17, Gelonghui reported that Aohua Endoscopy (688212.SH) announced that as of April 17, 2025, the company has repurchased a total of 1.3704 million shares through the centralized bidding trading system of the Shanghai Exchange, accounting for 1.02% of the company's total equity. The highest repurchase price was 41.99 yuan per share, the lowest was 37.50 yuan per share, and the total funds paid amount to 55.242 million yuan (excluding stamp duty, transaction commissions, and other trading fees).
Australasia Endoscope (688212.SH): Net loss of 28.7915 million yuan in the first quarter.
Gelonghui, April 17丨 Auhua Endoscopy (688212.SH) announced its first quarter report for 2025, with a revenue of 0.124 billion yuan, a year-on-year decrease of 26.92%; Net income attributable to shareholders of the listed company was -28.7915 million yuan; EPS was 0.21 yuan.
Why Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Shaky Earnings Are Just The Beginning Of Its Problems
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. Just Missed EPS By 71%: Here's What Analysts Think Will Happen Next
Why Investors Shouldn't Be Surprised By Shanghai Aohua Photoelectricity Endoscope Co., Ltd.'s (SHSE:688212) P/S
Australian Endoscopy: 2024 Annual Report
Australian Endoscopy: 2024 Annual Report Summary
2024 ANNUAL REPORT
2024 Annual Report Summary
Auhua Endoscopy (688212.SH) released its performance for the year 2024, with a net income of 21.01 million yuan, a year-on-year decrease of 63.68%.
Aohua Endoscopy (688212.SH) has disclosed its annual report for 2024, stating that the company achieved revenue of 0.75 billion yuan during the reporting period...
Aohua Endoscopy (688212.SH): The net income for 2024 is 21.0122 million yuan, a decrease of 63.68% year-on-year.
On April 9, Glenwood announced that Australia-China Endoscopy (688212.SH) published its annual report for 2024, achieving revenue of 0.75 billion yuan during the reporting period, a year-on-year increase of 10.54%; Net income attributable to shareholders of the listed company was 21.0122 million yuan, a year-on-year decrease of 63.68%; EPS was 0.16 yuan. It plans to distribute a cash dividend of 0.8 yuan (tax included) for every 10 shares to all shareholders.
Aohua Endoscope (688212.SH): Related Shareholders have collectively increased their Shareholding by 3.735 million yuan.
Gelonghui reported on March 21 that Aohua Endoscopy (688212.SH) announced that as of March 21, 2025, the relevant Shareholding entities accumulated 101,084 shares of the company through the centralized bidding trading method on the Shanghai Stock Exchange, accounting for 0.0750% of the company's total equity, with a total investment amount of 3.735 million yuan (excluding stamp duty, trading commissions, and other transaction costs), which has exceeded the lower limit of the current Shareholding plan, and the implementation of this Shareholding plan is complete. Names of the Shareholding entities: Director and Vice General Manager Mr. Chen Peng, Vice General Manager and Secretary of the Board of Directors Mr. Shi Xiaojiang, Vice.
Australian and Chinese Endoscopy: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Auhua Endoscopy (688212.SH): First buyback of 0.0991 million shares.
Gelonghui reported on February 26 that Australia Huanuo Medical (688212.SH) announced that on February 26, 2025, the company conducted its first share buyback by centralized bidding, repurchasing 99,050 shares, accounting for 0.07% of the total share capital of 134,587,250 shares. The highest transaction price was 40.00 yuan/share, the lowest price was 39.85 yuan/share, and the total amount paid was 3,955,494.08 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Aohua Endoscopy (688212.SH): The net income for the year 2024 is 21.3218 million yuan, a decrease of 63.15% year-on-year.
Aohua Endoscopy (688212.SH) released the 2024 performance preliminary report, during the reporting period the company achieved revenue of 7...
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) May Have Issues Allocating Its Capital